Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

NUVL

Nuvalent Inc

Sep 20 • 04:00PM ET

108.00

Dollar change +4.75
Percentage change 4.60	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VB XBI VBR VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.78	Insider Own	47.77%	Shs Outstand	58.63M	Perf Week	23.50%
Market Cap	7.54B	Forward P/E	-	EPS next Y	-4.22	Insider Trans	-4.01%	Shs Float	36.45M	Perf Month	30.66%
Income	-173.59M	PEG	-	EPS next Q	-0.94	Inst Own	60.06%	Short Float	18.85%	Perf Quarter	36.28%
Sales	0.00M	P/S	-	EPS this Y	-62.24%	Inst Trans	-1.03%	Short Ratio	15.89	Perf Half Y	35.78%
Book/sh	9.84	P/B	10.97	EPS next Y	-19.75%	ROA	-31.08%	Short Interest	6.87M	Perf Year	153.40%
Cash/sh	9.43	P/C	11.46	EPS next 5Y	-	ROE	-32.81%	52W Range	41.16 - 113.51	Perf YTD	46.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-72.54%	ROI	-27.25%	52W High	-4.85%	Beta	1.28
Dividend TTM	-	Quick Ratio	17.44	Sales past 5Y	0.00%	Gross Margin	-	52W Low	162.39%	ATR (14)	5.51
Dividend Ex-Date	-	Current Ratio	17.44	EPS Y/Y TTM	-50.43%	Oper. Margin	0.00%	RSI (14)	69.44	Volatility	9.02% 5.33%
Employees	92	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.17	Target Price	111.27
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-72.98%	Payout	-	Rel Volume	3.87	Prev Close	103.25
Sales Surprise	-	EPS Surprise	-15.32%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	432.47K	Price	108.00
SMA20	20.96%	SMA50	32.34%	SMA200	41.03%	Trades		Volume	1,673,017	Change	4.60%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-29-24	Initiated	Barclays	Overweight	$100
Apr-17-24	Initiated	Jefferies	Buy	$97
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform	$69 → $110
Feb-28-24	Resumed	Guggenheim	Buy	$99
Feb-23-24	Initiated	Robert W. Baird	Outperform	$105
Sep-27-23	Initiated	Stifel	Buy	$65
Aug-08-23	Initiated	SVB Securities	Market Perform	$42
Jul-24-23	Initiated	Guggenheim	Buy	$56
Jan-18-23	Initiated	Wedbush	Outperform	$39
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28

Sep-18-24 04:05PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire)
Sep-16-24 10:23PM	Nuvalent Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +28.27% -6.61%
04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily)
11:18AM	Cancer Biotech Nuvalents Stock Jumps on Positive Data (Barrons.com)
07:00AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
07:57PM	Loading…
Sep-14-24 07:57PM	Nuvalent, Inc. (NUVL): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
05:29PM	Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
05:00AM	Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines (PR Newswire)
Sep-13-24 09:53AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 (PR Newswire) +7.06%
Sep-09-24 06:30AM	Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles (PR Newswire)
Aug-29-24 06:30AM	Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-08-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-23-24 04:52AM	Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment (Clinical Trials Arena)
Jul-22-24 06:30AM	Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor (PR Newswire)
Jul-16-24 06:30AM	Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 (PR Newswire)
06:30AM	Loading…
Jul-11-24 06:30AM	Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer (PR Newswire)
Jun-24-24 06:00AM	3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally (InvestorPlace)
May-29-24 06:30AM	Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-17-24 04:48PM	Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing (MT Newswires)
06:31AM	FDA grants breakthrough therapy status for Nuvalents NVL-655 (Pharmaceutical Technology)
May-16-24 04:23PM	Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate (MT Newswires)
04:01PM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 (PR Newswire)
May-09-24 01:56PM	NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024 (InvestorPlace)
09:27AM	Nuvalent Q1 Loss Widens (RTT News)
07:19AM	Nuvalent Q1 Net Loss Widens (MT Newswires)
06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results (PR Newswire)
May-08-24 05:22PM	Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing (MT Newswires)
10:21AM	Why Earnings Season Could Be Great for Nuvalent (NUVL) (Zacks)
May-01-24 05:05PM	Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing (MT Newswires)
Apr-08-24 04:30PM	Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
07:00PM	Loading…
Apr-05-24 07:00PM	Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-29-24 07:01PM	Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-25-24 07:01PM	Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-19-24 07:01PM	Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-05-24 04:52PM	Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Feb-29-24 04:32AM	Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... (GuruFocus.com)
Feb-27-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
06:15AM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 (PR Newswire)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-12-24 06:30AM	Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors (PR Newswire)
Feb-01-24 06:30AM	Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (PR Newswire)
Jan-08-24 06:30AM	Nuvalent Announces 'OnTarget 2026' Operating Plan and Key Anticipated Milestones (PR Newswire)
Dec-22-23 03:01PM	Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Dec-21-23 01:01PM	Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30AM	Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-14-23 07:15PM	Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline Progress (GuruFocus.com)
06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-04-23 07:02AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Nov-01-23 06:30AM	Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 06:27PM	Why Nuvalent Stock Tanked on Tuesday (Motley Fool) -8.28%
Oct-16-23 09:55PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:30AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-13-23 06:30AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC (PR Newswire)
Oct-07-23 01:00AM	Insider Sell: Chief Medical Officer Christopher Turner Sells 7,995 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-05-23 07:13PM	Why Nuvalent Stock Skyrocketed 35% This Week (Motley Fool) +8.52%
10:29AM	Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data (Zacks)
01:01AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-04-23 04:13PM	Why Nuvalent Stock Was Soaring Wednesday (Motley Fool) +35.57%
12:21PM	Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile (PR Newswire)
Sep-18-23 06:30AM	Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium (PR Newswire) -6.08%
Sep-05-23 06:30AM	Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors (PR Newswire)
Aug-31-23 06:30AM	Nuvalent to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace)
Aug-10-23 06:30AM	Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-01-23 06:30AM	Nuvalent to Participate in Upcoming August Investor Conferences (PR Newswire)
Jul-21-23 08:50AM	Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why (Zacks)
Jun-07-23 08:50AM	Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-24-23 06:30AM	Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit (PR Newswire)
May-11-23 06:30AM	Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-19-23 06:30AM	Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days (PR Newswire) +5.13%
Apr-18-23 09:00AM	Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 (PR Newswire)
Apr-02-23 10:56AM	Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Mar-23-23 06:30AM	Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023) (PR Newswire)
Mar-16-23 06:30AM	Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire) +5.45%
Mar-14-23 05:59PM	Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023 (PR Newswire) +6.05% -6.24%
Mar-01-23 06:30AM	Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference (PR Newswire)
Jan-04-23 06:30AM	Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-23 09:40AM	Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year? (Zacks)
Dec-13-22 10:15AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 (PR Newswire)
Dec-12-22 03:44PM	12 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Dec-02-22 08:50AM	Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going (Zacks)
Nov-17-22 12:00PM	What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now? (Zacks)
Nov-10-22 06:30AM	Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-03-22 08:13PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire) -6.04% +5.13%
Oct-31-22 09:14PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire) -5.63%
07:15AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-28-22 04:18PM	Nuvalent stock jumps on positive data from cancer drug trial (American City Business Journals) +60.64%
04:06PM	Recent IPO Stock Nuvalent Is Flirting With A Record High On A Tricky Cancer Win (Investor's Business Daily)
11:10AM	Why Nuvalent Shares Are Surging 45% Today? (Benzinga)
12:01AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC (PR Newswire)
Oct-26-22 06:30AM	Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655 (PR Newswire)
Oct-23-22 09:26AM	We Think Nuvalent (NASDAQ:NUVL) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Oct-17-22 06:30AM	Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium (PR Newswire) +6.99%
Oct-06-22 06:30AM	Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors (PR Newswire)
Sep-20-22 10:16AM	Nuvalent Has Made a Base Pattern on the Charts (TheStreet.com)
Sep-07-22 06:30AM	Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates (PR Newswire) +17.55%
Sep-01-22 06:30AM	Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference (PR Newswire)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pelish Henry E.	Chief Scientific Officer	Sep 16 '24	Sale	98.92	32,795	3,244,140	33,300	Sep 18 04:53 PM
Miller Deborah Ann	Chief Legal Officer	Sep 16 '24	Option Exercise	18.93	8,000	151,440	41,300	Sep 18 04:50 PM
Miller Deborah Ann	Chief Legal Officer	Sep 16 '24	Sale	96.47	8,000	771,798	33,300	Sep 18 04:50 PM
Miller Deborah Ann	Chief Legal Officer	Sep 09 '24	Option Exercise	6.89	3,000	20,670	36,300	Sep 11 04:55 PM
Miller Deborah Ann	Chief Legal Officer	Sep 09 '24	Sale	88.18	3,000	264,546	33,300	Sep 11 04:55 PM
Noci Darlene	Chief Development Officer	Sep 03 '24	Option Exercise	18.93	5,000	94,650	38,300	Sep 04 07:52 PM
Noci Darlene	Chief Development Officer	Sep 03 '24	Sale	84.43	5,000	422,146	33,300	Sep 04 07:52 PM
Balcom Alexandra	Chief Financial Officer	Aug 30 '24	Option Exercise	27.85	10,000	278,500	43,300	Sep 04 04:52 PM
Balcom Alexandra	Chief Financial Officer	Aug 30 '24	Sale	84.23	10,000	842,349	33,300	Sep 04 04:52 PM
Shair Matthew	Director	Aug 26 '24	Sale	84.46	2,000	168,914	228,522	Aug 27 04:51 PM
Pelish Henry E.	Chief Scientific Officer	Aug 23 '24	Sale	85.08	10,500	893,340	66,095	Aug 27 04:49 PM
Miller Deborah Ann	Chief Legal Officer	Aug 23 '24	Option Exercise	23.80	11,000	261,750	44,300	Aug 27 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Aug 23 '24	Sale	85.04	11,000	935,440	33,300	Aug 27 04:47 PM
Conley Emily	Director	Aug 23 '24	Option Exercise	13.79	3,334	45,976	5,841	Aug 27 04:44 PM
Conley Emily	Director	Aug 23 '24	Sale	85.02	3,334	283,457	2,507	Aug 27 04:44 PM
Henry Pelish	Chief Scientific Officer	Aug 23 '24	Proposed Sale	84.13	43,295	3,642,408		Aug 23 04:07 PM
Miller Deborah Ann	Chief Legal Officer	Aug 08 '24	Option Exercise	6.89	3,000	20,670	36,300	Aug 09 04:48 PM
Miller Deborah Ann	Chief Legal Officer	Aug 08 '24	Sale	68.78	3,000	206,348	33,300	Aug 09 04:48 PM
Noci Darlene	Chief Development Officer	Aug 01 '24	Option Exercise	18.93	5,000	94,650	38,300	Aug 02 04:45 PM
Noci Darlene	Chief Development Officer	Aug 01 '24	Sale	77.22	5,000	386,125	33,300	Aug 02 04:45 PM
Balcom Alexandra	Chief Financial Officer	Jul 31 '24	Option Exercise	27.85	10,000	278,500	43,300	Aug 02 04:43 PM
Balcom Alexandra	Chief Financial Officer	Jul 31 '24	Sale	79.51	10,000	795,074	33,300	Aug 02 04:43 PM
Shair Matthew	Director	Jul 29 '24	Sale	79.59	2,000	159,176	230,522	Jul 31 04:46 PM
Matthew Shair	Director	Jul 29 '24	Proposed Sale	81.68	8,000	653,440		Jul 29 04:09 PM
Conley Emily	Director	Jul 15 '24	Option Exercise	13.79	5,000	68,950	7,507	Jul 16 04:47 PM
Conley Emily	Director	Jul 15 '24	Sale	80.72	5,000	403,621	2,507	Jul 16 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Jul 12 '24	Option Exercise	27.85	6,000	167,100	39,300	Jul 16 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jul 12 '24	Sale	80.16	6,000	480,960	33,300	Jul 16 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jul 08 '24	Option Exercise	6.89	3,000	20,670	36,300	Jul 10 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jul 08 '24	Sale	73.23	3,000	219,687	33,300	Jul 10 04:45 PM
Noci Darlene	Chief Development Officer	Jul 01 '24	Option Exercise	18.93	5,000	94,650	38,300	Jul 02 04:47 PM
Noci Darlene	Chief Development Officer	Jul 01 '24	Sale	75.54	5,000	377,696	33,300	Jul 02 04:47 PM
Balcom Alexandra	Chief Financial Officer	Jun 28 '24	Option Exercise	27.85	10,000	278,500	43,300	Jul 02 04:44 PM
Balcom Alexandra	Chief Financial Officer	Jun 28 '24	Sale	75.43	10,000	754,341	33,300	Jul 02 04:44 PM
Shair Matthew	Director	Jun 24 '24	Sale	80.22	2,000	160,438	232,522	Jun 26 04:54 PM
Conley Emily	Director	Jun 14 '24	Option Exercise	13.79	5,000	68,950	7,507	Jun 18 04:15 PM
Conley Emily	Director	Jun 14 '24	Sale	77.56	5,000	387,776	2,507	Jun 18 04:15 PM
Miller Deborah Ann	Chief Legal Officer	Jun 06 '24	Option Exercise	14.41	8,000	115,320	41,300	Jun 07 04:44 PM
Miller Deborah Ann	Chief Legal Officer	Jun 06 '24	Sale	80.40	8,000	643,213	33,300	Jun 07 04:44 PM
Shair Matthew	Director	May 28 '24	Sale	67.22	2,000	134,438	234,522	May 29 04:43 PM
Conley Emily	Director	May 15 '24	Option Exercise	12.31	5,000	61,565	5,008	May 17 04:41 PM
Conley Emily	Director	May 15 '24	Sale	69.09	5,000	345,450	8	May 17 04:41 PM
Shair Matthew	Director	May 13 '24	Sale	65.84	37,500	2,468,866	1,424,698	May 15 04:54 PM
Shair Matthew	Director	May 06 '24	Sale	69.48	37,500	2,605,525	1,462,198	May 08 04:51 PM
Miller Deborah Ann	Chief Legal Officer	May 02 '24	Option Exercise	6.89	3,000	20,670	36,300	May 03 04:47 PM
Miller Deborah Ann	Chief Legal Officer	May 02 '24	Sale	72.07	3,000	216,203	33,300	May 03 04:47 PM
Shair Matthew	Director	Apr 29 '24	Sale	67.51	37,500	2,531,537	1,499,698	May 01 04:41 PM
Shair Matthew	Director	Apr 29 '24	Sale	67.51	2,000	135,018	236,522	May 01 04:41 PM
Shair Matthew	Director	Apr 22 '24	Sale	63.65	37,500	2,386,910	1,537,198	Apr 24 04:44 PM
Shair Matthew	Director	Apr 15 '24	Sale	65.56	37,500	2,458,335	1,574,698	Apr 17 04:46 PM
Conley Emily	Director	Apr 15 '24	Option Exercise	9.36	5,000	46,800	5,008	Apr 17 04:44 PM
Conley Emily	Director	Apr 15 '24	Sale	65.52	5,000	327,607	8	Apr 17 04:44 PM
Shair Matthew	Director	Apr 08 '24	Sale	68.44	37,500	2,566,479	1,612,198	Apr 10 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Apr 04 '24	Option Exercise	6.89	3,000	20,670	36,300	Apr 05 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Apr 04 '24	Sale	73.60	3,000	220,787	33,300	Apr 05 04:47 PM
Shair Matthew	Director	Apr 01 '24	Sale	76.92	37,500	2,884,337	1,649,698	Apr 03 04:45 PM
Hack Andrew A. F.	Director	Mar 27 '24	Sale	72.77	880,000	64,035,959	2,697,267	Mar 29 05:15 PM
Miller Deborah Ann	Chief Legal Officer	Mar 28 '24	Option Exercise	22.58	22,000	496,740	55,300	Mar 29 04:46 PM
Miller Deborah Ann	Chief Legal Officer	Mar 28 '24	Sale	75.20	22,000	1,654,311	33,300	Mar 29 04:46 PM
Shair Matthew	Director	Mar 25 '24	Sale	76.77	37,500	2,878,982	1,687,198	Mar 27 04:55 PM
Shair Matthew	Director	Mar 25 '24	Sale	76.77	2,000	153,546	238,522	Mar 27 04:55 PM
Noci Darlene	Chief Development Officer	Mar 22 '24	Option Exercise	7.74	20,000	154,800	53,300	Mar 25 04:49 PM
Noci Darlene	Chief Development Officer	Mar 22 '24	Sale	77.51	20,000	1,550,229	33,300	Mar 25 04:49 PM
Conley Emily	Director	Mar 15 '24	Option Exercise	9.36	13,333	124,797	13,341	Mar 19 04:46 PM
Conley Emily	Director	Mar 15 '24	Sale	80.92	13,333	1,078,883	8	Mar 19 04:46 PM
Shair Matthew	Director	Dec 26 '23	Sale	75.12	69,602	5,228,346	1,774,246	Dec 28 05:09 PM
Shair Matthew	Director	Dec 28 '23	Sale	75.46	48,548	3,663,492	1,724,698	Dec 28 05:09 PM
Shair Matthew	Director	Dec 27 '23	Sale	75.17	1,000	75,170	1,773,246	Dec 28 05:09 PM
Protopapas Anna	Director	Dec 18 '23	Option Exercise	9.36	5,000	46,800	5,000	Dec 20 04:58 PM
Protopapas Anna	Director	Dec 18 '23	Sale	75.67	5,000	378,350	0	Dec 20 04:58 PM
Noci Darlene	Chief Development Officer	Dec 18 '23	Option Exercise	4.70	40,000	188,139	40,000	Dec 20 04:56 PM
Noci Darlene	Chief Development Officer	Dec 18 '23	Sale	75.82	40,000	3,032,800	0	Dec 20 04:56 PM
Miller Deborah Ann	Chief Legal Officer	Dec 18 '23	Option Exercise	27.85	33,046	920,331	33,046	Dec 20 04:54 PM
Miller Deborah Ann	Chief Legal Officer	Dec 19 '23	Option Exercise	18.93	5,000	94,650	5,000	Dec 20 04:54 PM
Miller Deborah Ann	Chief Legal Officer	Dec 18 '23	Sale	75.82	33,046	2,505,548	0	Dec 20 04:54 PM
Miller Deborah Ann	Chief Legal Officer	Dec 19 '23	Sale	75.00	5,000	375,000	0	Dec 20 04:54 PM
Balcom Alexandra	Chief Financial Officer	Dec 18 '23	Option Exercise	1.08	30,000	32,400	30,000	Dec 20 04:51 PM
Balcom Alexandra	Chief Financial Officer	Dec 18 '23	Sale	75.82	30,000	2,274,600	0	Dec 20 04:51 PM
Shair Matthew	Director	Nov 28 '23	Sale	61.89	9,150	566,303	1,843,848	Nov 30 04:47 PM
Noci Darlene	Chief Development Officer	Nov 01 '23	Option Exercise	1.08	3,000	3,240	3,000	Nov 03 04:43 PM
Noci Darlene	Chief Development Officer	Nov 01 '23	Sale	52.66	3,000	157,975	0	Nov 03 04:43 PM
Shair Matthew	Director	Oct 24 '23	Sale	50.70	91,700	4,648,872	1,852,998	Oct 26 04:47 PM
Turner Christopher Durant	Chief Medical Officer	Oct 04 '23	Option Exercise	6.89	7,995	55,086	22,508	Oct 06 04:58 PM
Turner Christopher Durant	Chief Medical Officer	Oct 04 '23	Sale	54.04	7,995	432,031	14,513	Oct 06 04:58 PM
Noci Darlene	Chief Development Officer	Oct 04 '23	Option Exercise	5.56	20,000	111,150	20,000	Oct 06 04:56 PM
Noci Darlene	Chief Development Officer	Oct 04 '23	Sale	55.99	20,000	1,119,702	0	Oct 06 04:56 PM
Noci Darlene	Chief Development Officer	Oct 02 '23	Option Exercise	1.08	3,000	3,240	3,000	Oct 04 04:24 PM
Noci Darlene	Chief Development Officer	Oct 02 '23	Sale	45.88	3,000	137,649	0	Oct 04 04:24 PM

Dollar change -0.15
Percentage change -1.30	%

DVAX Dynavax Technologies Corp. daily Stock Chart

Held by: IJR VTI IWM XBI VXF IJT SPSM IBB IWO SLYG

Index	RUT	P/E	103.84	EPS (ttm)	0.11	Insider Own	0.49%	Shs Outstand	131.04M	Perf Week	1.61%
Market Cap	1.49B	Forward P/E	30.80	EPS next Y	0.37	Insider Trans	-0.56%	Shs Float	130.41M	Perf Month	-0.26%
Income	17.18M	PEG	-	EPS next Q	0.12	Inst Own	102.51%	Short Float	14.03%	Perf Quarter	-0.70%
Sales	249.69M	P/S	5.96	EPS this Y	489.28%	Inst Trans	-1.81%	Short Ratio	8.22	Perf Half Y	-6.66%
Book/sh	4.91	P/B	2.31	EPS next Y	89.32%	ROA	1.76%	Short Interest	18.30M	Perf Year	-15.86%
Cash/sh	5.61	P/C	2.02	EPS next 5Y	-	ROE	2.82%	52W Range	9.74 - 15.15	Perf YTD	-18.81%
Dividend Est.	-	P/FCF	42.10	EPS past 5Y	54.52%	ROI	1.92%	52W High	-25.08%	Beta	1.37
Dividend TTM	-	Quick Ratio	13.18	Sales past 5Y	239.63%	Gross Margin	82.03%	52W Low	16.53%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	14.18	EPS Y/Y TTM	-84.76%	Oper. Margin	-5.01%	RSI (14)	54.88	Volatility	2.62% 2.77%
Employees	408	Debt/Eq	0.40	Sales Y/Y TTM	-45.65%	Profit Margin	6.88%	Recom	1.40	Target Price	24.50
Option/Short	Yes / Yes	LT Debt/Eq	0.39	EPS Q/Q	207.12%	Payout	-	Rel Volume	2.10	Prev Close	11.50
Sales Surprise	-2.96%	EPS Surprise	24.03%	Sales Q/Q	22.48%	Earnings	Aug 06 AMC	Avg Volume	2.23M	Price	11.35
SMA20	1.92%	SMA50	2.97%	SMA200	-6.09%	Trades		Volume	4,680,140	Change	-1.30%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-01-24	Initiated	Goldman	Neutral	$20
Sep-27-22	Initiated	JMP Securities	Mkt Outperform	$22
Jan-06-22	Resumed	Goldman	Buy	$38
Aug-06-21	Initiated	Goldman	Buy	$19
Aug-07-20	Reiterated	H.C. Wainwright	Buy	$14 → $12
Aug-03-20	Reiterated	H.C. Wainwright	Buy	$12 → $14
Jun-15-20	Initiated	Evercore ISI	Outperform	$14
Oct-18-19	Initiated	H.C. Wainwright	Buy	$13
Jul-11-19	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$20
Feb-27-19	Reiterated	Cantor Fitzgerald	Overweight	$32 → $28
May-10-18	Upgrade	JP Morgan	Neutral → Overweight
Mar-08-18	Reiterated	Cantor Fitzgerald	Overweight	$25 → $27
Feb-14-18	Downgrade	JP Morgan	Overweight → Neutral
Sep-25-17	Reiterated	RBC Capital Mkts	Outperform	$26 → $28
Sep-15-17	Initiated	Cantor Fitzgerald	Overweight	$24
Jul-31-17	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7 → $26
Jul-31-17	Upgrade	JP Morgan	Neutral → Overweight
May-09-17	Reiterated	RBC Capital Mkts	Sector Perform	$6 → $7
Apr-28-16	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$48 → $17
Apr-27-16	Downgrade	JP Morgan	Overweight → Neutral

Show Previous Ratings

Sep-16-24 07:02PM	Deep Track Capital, LP Increases Stake in Dynavax Technologies Corp (GuruFocus.com)
Sep-12-24 01:13AM	Federated Hermes, Inc. Reduces Stake in Dynavax Technologies Corp (GuruFocus.com)
Sep-05-24 08:30AM	Lantheus Appoints Julie Eastland as New Board Member (GlobeNewswire)
Aug-09-24 09:55AM	How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98% (Zacks)
Aug-06-24 11:30PM	Dynavax Technologies (DVAX) Q2 2024 Earnings Call Transcript (Motley Fool) +6.97%
07:10PM	Loading…
07:10PM	Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates (Zacks)
06:11PM	Dynavax Technologies: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates (PR Newswire)
Jul-23-24 04:00PM	Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 (PR Newswire)
Jun-28-24 04:32AM	Dynavax doses first subject in Phase I/II shingles vaccine trial (Clinical Trials Arena)
Jun-27-24 04:09PM	Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program (PR Newswire)
May-28-24 04:18PM	Dynavax to Present at Upcoming Investor Conferences (PR Newswire)
May-14-24 09:59AM	Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data (MT Newswires)
08:55AM	UPDATE 1-US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine (Reuters)
08:30AM	Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B Regimen for Adults on Hemodialysis in the U.S. (PR Newswire)
01:43PM	Loading…
May-10-24 01:43PM	Dynavax Technologies Corp (DVAX) Q1 2024 Earnings: Aligns with EPS Projections, Surpasses ... (GuruFocus.com)
May-09-24 01:58PM	Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.49%
03:40AM	Dynavax Technologies Corp (DVAX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue ... (GuruFocus.com)
02:15AM	Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript (Motley Fool)
May-08-24 08:59PM	DVAX Stock Earnings: Dynavax Technologies Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:20PM	Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Dynavax Technologies: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates (PR Newswire)
Apr-24-24 04:05PM	Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 (PR Newswire)
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Mar-04-24 11:53PM	Chief Accounting Officer Justin Burgess Sells Shares of Dynavax Technologies Corp (DVAX) (GuruFocus.com)
08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-27-24 06:54PM	Dynavax to Present at TD Cowen's 44th Annual Health Care Conference (PR Newswire)
Feb-23-24 10:34AM	Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:38AM	Q4 2023 Dynavax Technologies Corp Earnings Call (Thomson Reuters StreetEvents)
08:00PM	Loading…
Feb-22-24 08:00PM	Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript (Motley Fool)
05:15PM	Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4 (Zacks)
04:44PM	Dynavax Technologies Corp (DVAX) Reports Robust Revenue Growth and Market Leadership in 2023 (GuruFocus.com)
04:01PM	Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance (PR Newswire)
Feb-08-24 04:15PM	Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024 (PR Newswire)
Jan-08-24 10:58PM	3 Stocks Set to Soar 68% to 200% Higher (InvestorPlace) -5.22%
09:00AM	Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights (PR Newswire)
Jan-05-24 08:50AM	Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
03:03AM	Insider Sell: Dynavax Technologies Corp President & COO David Novack Sells 9,000 Shares (GuruFocus.com)
Jan-03-24 06:33PM	Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-05-23 09:55AM	Can Dynavax Technologies (DVAX) Climb 91.59% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-24-23 09:40AM	Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-20-23 05:04PM	Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-07-23 09:40AM	Is Dynavax Technologies (DVAX) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-04-23 09:02AM	Insider Sell: President & COO David Novack Sells 20,000 Shares of Dynavax Technologies Corp (GuruFocus.com)
Nov-03-23 12:28PM	Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised (Zacks)
10:46AM	Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2023 Earnings Call Transcript (Insider Monkey)
05:31AM	Dynavax Technologies (DVAX) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-02-23 06:22PM	Dynavax Technologies Corp (DVAX) Reports 66% YoY Increase in Q3 2023 HEPLISAV-B Revenue (GuruFocus.com)
04:39PM	Dynavax Technologies: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance (PR Newswire)
11:23AM	Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View (Zacks)
Nov-01-23 12:03PM	Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-30-23 10:00AM	Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-26-23 04:15PM	Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 (PR Newswire)
12:00PM	Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat (Zacks)
10:02AM	Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-24-23 07:45AM	Dynavax (DVAX) to Report Q3 Earnings: Will It Beat Estimates? (Zacks)
Oct-19-23 01:15PM	Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference (PR Newswire)
06:32AM	Is it a Good Idea to Invest in Dynavax (DVAX) Stock Now? (Zacks)
Oct-16-23 09:55AM	Wall Street Analysts See an 80.27% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High? (Zacks)
08:50AM	Here's Why Momentum in Dynavax Technologies (DVAX) Should Keep going (Zacks)
Oct-12-23 10:42AM	Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals (Zacks)
Oct-11-23 09:24AM	Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update (Zacks)
Oct-05-23 05:01AM	Insider Sell: President & COO David Novack Sells 40,000 Shares of Dynavax Technologies Corp (GuruFocus.com)
Sep-29-23 09:55AM	Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 73.92%: Read This Before Placing a Bet (Zacks)
08:50AM	Here's What Could Help Dynavax Technologies (DVAX) Maintain Its Recent Price Strength (Zacks)
Sep-28-23 11:18AM	Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why (Zacks)
10:48AM	Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent (Zacks)
Sep-26-23 11:49AM	Unveiling Dynavax Technologies (DVAX)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-21-23 09:19AM	Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study (Zacks)
Sep-20-23 07:51AM	Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients (Zacks)
Sep-18-23 09:16AM	GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia (Zacks)
Sep-14-23 09:36AM	Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod (Zacks)
Sep-12-23 08:26AM	Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up (Zacks)
07:54AM	Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up (Zacks)
Sep-11-23 12:31PM	J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe (Zacks)
08:21AM	Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up (Zacks)
Sep-08-23 07:06PM	Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe (Zacks)
Sep-07-23 08:43AM	J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit (Zacks)
Sep-06-23 04:05PM	Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
09:33AM	AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication (Zacks)
Sep-05-23 09:40AM	Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why (Zacks)
Sep-04-23 10:51AM	Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why (Zacks)
Aug-28-23 09:55AM	Wall Street Analysts Believe Dynavax Technologies (DVAX) Could Rally 66.21%: Here's is How to Trade (Zacks)
Aug-24-23 08:50AM	What Makes Dynavax Technologies (DVAX) a Good Fit for 'Trend Investing' (Zacks)
Aug-22-23 11:56AM	Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher (Zacks)
10:18AM	Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why (Zacks)
Aug-16-23 01:21PM	Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies (Zacks)
Aug-11-23 05:26AM	Insider Sell: President & COO David Novack Sells 40,000 Shares of Dynavax Technologies Corp ... (GuruFocus.com)
Aug-10-23 11:50AM	Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View (Zacks)
09:55AM	Wall Street Analysts See a 70.61% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High? (Zacks)
Aug-07-23 03:06PM	Dynavax Technologies Stock Sees Renewed Technical Strength (Investor's Business Daily)
Aug-06-23 07:00AM	Getting Another Shot of Biotech Dynavax Technologies (TheStreet.com)
Aug-04-23 12:53PM	Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2023 Earnings Call Transcript (Insider Monkey) +8.29%
01:00AM	Dynavax Technologies (DVAX) Q2 2023 Earnings Call Transcript (Motley Fool)
Aug-03-23 06:55PM	Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates (Zacks)
05:45PM	Dynavax Technologies: Q2 Earnings Snapshot (AP Finance)
04:05PM	Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance (PR Newswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CANO FRANCIS	Director	May 31 '24	Sale	11.93	3,615	43,127	36,905	Jun 03 05:37 PM
CANO FRANCIS	Director	May 24 '24	Option Exercise	5.90	7,500	44,250	44,405	May 28 08:18 PM
Burgess Justin	Chief Accounting Officer	Mar 01 '24	Option Exercise	10.45	7,101	74,232	20,526	Mar 04 05:25 PM
Burgess Justin	Chief Accounting Officer	Mar 01 '24	Sale	12.78	20,526	262,322	0	Mar 04 05:25 PM
Janssen Robert	SVP and CMO	Jan 04 '24	Option Exercise	9.41	1,500	14,115	51,425	Jan 08 06:48 PM
Janssen Robert	SVP and CMO	Jan 04 '24	Sale	15.00	1,500	22,500	49,925	Jan 08 06:48 PM
Novack David F	President & COO	Jan 02 '24	Option Exercise	5.42	9,000	48,780	12,187	Jan 04 07:04 PM
Novack David F	President & COO	Jan 02 '24	Sale	14.45	9,000	130,050	3,187	Jan 04 07:04 PM
Novack David F	President & COO	Dec 01 '23	Option Exercise	5.42	20,000	108,400	23,187	Dec 05 07:12 PM
Novack David F	President & COO	Dec 01 '23	Sale	13.56	20,000	271,200	3,187	Dec 05 07:12 PM
Novack David F	President & COO	Nov 03 '23	Option Exercise	5.42	20,000	108,400	23,187	Nov 07 05:16 PM
Novack David F	President & COO	Nov 03 '23	Sale	15.00	20,000	300,000	3,187	Nov 07 05:16 PM
Novack David F	President & COO	Nov 01 '23	Option Exercise	5.42	20,000	108,400	23,187	Nov 03 04:32 PM
Novack David F	President & COO	Nov 01 '23	Sale	14.12	20,000	282,400	3,187	Nov 03 04:32 PM
Janssen Robert	SVP and CMO	Oct 10 '23	Option Exercise	9.41	1,755	16,515	51,680	Oct 11 08:53 PM
Janssen Robert	SVP and CMO	Oct 10 '23	Sale	15.01	1,755	26,343	49,925	Oct 11 08:53 PM
Novack David F	President & COO	Oct 02 '23	Option Exercise	5.42	40,000	216,800	43,187	Oct 04 04:35 PM
Novack David F	President & COO	Oct 02 '23	Sale	14.88	40,000	595,000	3,187	Oct 04 04:35 PM
Janssen Robert	SVP and CMO	Oct 02 '23	Option Exercise	9.41	5,015	47,191	54,940	Oct 03 08:26 PM
Janssen Robert	SVP and CMO	Oct 02 '23	Sale	15.03	5,015	75,375	49,925	Oct 03 08:26 PM

NUVL

Nuvalent Inc

DVAX

Dynavax Technologies Corp.

Upgrade your FINVIZ experience